[SCHEDULE 13G/A] Xenon Pharmaceuticals Inc SEC Filing
Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.
Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.
Filing: Schedule 13G/A da FMR LLC e Abigail P. Johnson che dichiara la partecipazione beneficiaria in XENON PHARMACEUTICALS INC (CUSIP 98420N105). La dichiarazione riporta come data dell'evento il 06/30/2025 e firma in data 08/05/2025.
Holdings: La partecipazione beneficiaria complessiva 猫 di 8,824,363 azioni, pari al 11.5% della classe. Nei dati di copertina FMR LLC indica potere di voto esclusivo su 8,824,348 azioni, potere di disposizione esclusivo su 8,824,363 azioni e nessun potere di voto/disposizione condiviso. Abigail P. Johnson risulta con potere di disposizione esclusivo su 8,824,363 azioni e nessun potere di voto indicato. La dichiarazione specifica che i titoli sono stati acquisiti e sono detenuti nel normale corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo dell'emittente. Sono richiamati l'Exhibit 99 e l'Exhibit 24 (procura).
Filing: Schedule 13G/A presentado por FMR LLC y Abigail P. Johnson que informa titularidad beneficiaria en XENON PHARMACEUTICALS INC (CUSIP 98420N105). La declaraci贸n refleja fecha del evento 06/30/2025 y firma fechada 08/05/2025.
Holdings: La titularidad beneficiaria agregada es de 8,824,363 acciones, que representan el 11.5% de la clase. En los datos de portada FMR LLC informa poder de voto exclusivo sobre 8,824,348 acciones, poder de disposici贸n exclusivo sobre 8,824,363 acciones, y ning煤n poder de voto/disposici贸n compartido. A Abigail P. Johnson se le atribuye poder de disposici贸n exclusivo sobre 8,824,363 acciones y ning煤n poder de voto consignado. La presentaci贸n indica que los valores fueron adquiridos y se mantienen en el curso ordinario de los negocios y no para cambiar o influir en el control del emisor. Se hace referencia al Exhibit 99 y al Exhibit 24 (poder).
Filing: FMR LLC 氚� Abigail P. Johnson鞐� 鞚橅暅 Schedule 13G/A 鞝滌稖搿� XENON PHARMACEUTICALS INC (CUSIP 98420N105)鞐� 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 氤搓碃頃╇媹雼�. 靹彪獏靹滊姅 靷贝鞚检潉 06/30/2025搿�, 靹滊獏鞚检潉 08/05/2025搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟.
Holdings: 齑� 靾橃澋鞝� 靻岇湢甓岇潃 8,824,363欤�搿� 頃措嫻 韥措灅鞀れ潣 11.5%毳� 彀頃╇媹雼�. 響滌 雿办澊韯办棎靹� FMR LLC電� 雼弲 鞚橁舶甓� 8,824,348欤�, 雼弲 觳橂秳甓� 8,824,363欤�毳� 氤搓碃頃橂┌ 瓿惦彊 鞚橁舶甓�/觳橂秳甓岇潃 鞐嗠嫟瓿� 旮办灛頄堨姷雼堧嫟. Abigail P. Johnson鞚� 雼弲 觳橂秳甓� 8,824,363欤�鞙茧 氤搓碃霅橂┌ 鞚橁舶甓岇潃 鞐嗢潓鞙茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 頃措嫻 歃濌秾鞚� 鞝曥儊鞝侅澑 鞓侅梾瓿检爼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 氚滍枆鞚胳潣 歆�氚半ゼ 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�. Exhibit 99 氚� Exhibit 24(鞙勳瀯鞛�)臧� 彀胳“霅╇媹雼�.
Filing: Schedule 13G/A d茅pos茅 par FMR LLC et Abigail P. Johnson d茅clarant une d茅tention b茅n茅ficiaire dans XENON PHARMACEUTICALS INC (CUSIP 98420N105). La d茅claration indique une date d'茅v茅nement au 06/30/2025 et une signature dat茅e du 08/05/2025.
Holdings: La d茅tention b茅n茅ficiaire agr茅g茅e s'茅l猫ve 脿 8,824,363 actions, repr茅sentant 11.5% de la cat茅gorie. Sur la page de couverture, FMR LLC d茅clare un pouvoir de vote exclusif sur 8,824,348 actions, un pouvoir de disposition exclusif sur 8,824,363 actions, et aucun pouvoir de vote/disposition partag茅. Abigail P. Johnson est indiqu茅e avec un pouvoir de disposition exclusif sur 8,824,363 actions et aucun pouvoir de vote inscrit. Le d茅p么t pr茅cise que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur. L'Exhibit 99 et l'Exhibit 24 (procuration) sont mentionn茅s.
Filing: Schedule 13G/A eingereicht von FMR LLC und Abigail P. Johnson, die eine wirtschaftliche Beteiligung an XENON PHARMACEUTICALS INC (CUSIP 98420N105) melden. Die Erkl盲rung weist ein Ereignisdatum vom 06/30/2025 und ein Unterschriftsdatum vom 08/05/2025 aus.
Holdings: Die aggregierte wirtschaftliche Beteiligung betr盲gt 8,824,363 Aktien, was 11.5% der Klasse entspricht. Auf den Deckbl盲ttern meldet FMR LLC alleiniges Stimmrecht f眉r 8,824,348 Aktien, alleiniges Verf眉gungsrecht f眉r 8,824,363 Aktien und keine geteilten Stimm- oder Verf眉gungsrechte. Abigail P. Johnson wird mit alleinigem Verf眉gungsrecht 眉ber 8,824,363 Aktien und keinem Stimmrecht ausgewiesen. Die Einreichung gibt an, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten werden und nicht dazu dienen, die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen. Exhibit 99 und Exhibit 24 (Vollmacht) werden genannt.
- FMR LLC and Abigail P. Johnson beneficially own 8,824,363 shares (11.5%)
- Filing certifies securities were acquired and are held in the ordinary course and not to influence control
- Specific voting and dispositive power figures are disclosed on the cover page
- None.
Insights
TL;DR: FMR LLC and Abigail P. Johnson report a sizable 11.5% passive stake in XENE; holdings appear reported as held in the ordinary course.
The filing discloses 8,824,363 shares (11.5%) beneficially owned as of the 06/30/2025 event date, with FMR LLC showing near-parity sole voting and dispositive figures and Abigail P. Johnson listed with sole dispositive power but no voting power. Item 10 certifies the position was not acquired to influence control. For investors, this is material ownership disclosure but the filing explicitly characterizes the position as passive and ordinary-course, and no schedule 13D-level activist intent or additional transactions are disclosed in the document.
TL;DR: A >5% stake is disclosed, but the filing affirms a passive posture and reports no shared control; governance implications appear limited per the statement.
The Schedule 13G/A lists FMR LLC and Abigail P. Johnson as reporting persons and documents specific voting/dispositive figures: FMR LLC sole voting 8,824,348, sole dispositive 8,824,363; Abigail P. Johnson sole dispositive 8,824,363, no voting power. The certification in Item 10 states holdings were not acquired to change or influence control. The filing references Exhibit 99 for the 13d-1(k)(1) agreement and a power of attorney (Exhibit 24) incorporated by reference, which are administrative items relevant to legal form but do not, in this document, indicate governance action.
Filing: Schedule 13G/A da FMR LLC e Abigail P. Johnson che dichiara la partecipazione beneficiaria in XENON PHARMACEUTICALS INC (CUSIP 98420N105). La dichiarazione riporta come data dell'evento il 06/30/2025 e firma in data 08/05/2025.
Holdings: La partecipazione beneficiaria complessiva 猫 di 8,824,363 azioni, pari al 11.5% della classe. Nei dati di copertina FMR LLC indica potere di voto esclusivo su 8,824,348 azioni, potere di disposizione esclusivo su 8,824,363 azioni e nessun potere di voto/disposizione condiviso. Abigail P. Johnson risulta con potere di disposizione esclusivo su 8,824,363 azioni e nessun potere di voto indicato. La dichiarazione specifica che i titoli sono stati acquisiti e sono detenuti nel normale corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo dell'emittente. Sono richiamati l'Exhibit 99 e l'Exhibit 24 (procura).
Filing: Schedule 13G/A presentado por FMR LLC y Abigail P. Johnson que informa titularidad beneficiaria en XENON PHARMACEUTICALS INC (CUSIP 98420N105). La declaraci贸n refleja fecha del evento 06/30/2025 y firma fechada 08/05/2025.
Holdings: La titularidad beneficiaria agregada es de 8,824,363 acciones, que representan el 11.5% de la clase. En los datos de portada FMR LLC informa poder de voto exclusivo sobre 8,824,348 acciones, poder de disposici贸n exclusivo sobre 8,824,363 acciones, y ning煤n poder de voto/disposici贸n compartido. A Abigail P. Johnson se le atribuye poder de disposici贸n exclusivo sobre 8,824,363 acciones y ning煤n poder de voto consignado. La presentaci贸n indica que los valores fueron adquiridos y se mantienen en el curso ordinario de los negocios y no para cambiar o influir en el control del emisor. Se hace referencia al Exhibit 99 y al Exhibit 24 (poder).
Filing: FMR LLC 氚� Abigail P. Johnson鞐� 鞚橅暅 Schedule 13G/A 鞝滌稖搿� XENON PHARMACEUTICALS INC (CUSIP 98420N105)鞐� 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 氤搓碃頃╇媹雼�. 靹彪獏靹滊姅 靷贝鞚检潉 06/30/2025搿�, 靹滊獏鞚检潉 08/05/2025搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟.
Holdings: 齑� 靾橃澋鞝� 靻岇湢甓岇潃 8,824,363欤�搿� 頃措嫻 韥措灅鞀れ潣 11.5%毳� 彀頃╇媹雼�. 響滌 雿办澊韯办棎靹� FMR LLC電� 雼弲 鞚橁舶甓� 8,824,348欤�, 雼弲 觳橂秳甓� 8,824,363欤�毳� 氤搓碃頃橂┌ 瓿惦彊 鞚橁舶甓�/觳橂秳甓岇潃 鞐嗠嫟瓿� 旮办灛頄堨姷雼堧嫟. Abigail P. Johnson鞚� 雼弲 觳橂秳甓� 8,824,363欤�鞙茧 氤搓碃霅橂┌ 鞚橁舶甓岇潃 鞐嗢潓鞙茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 頃措嫻 歃濌秾鞚� 鞝曥儊鞝侅澑 鞓侅梾瓿检爼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 氚滍枆鞚胳潣 歆�氚半ゼ 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�. Exhibit 99 氚� Exhibit 24(鞙勳瀯鞛�)臧� 彀胳“霅╇媹雼�.
Filing: Schedule 13G/A d茅pos茅 par FMR LLC et Abigail P. Johnson d茅clarant une d茅tention b茅n茅ficiaire dans XENON PHARMACEUTICALS INC (CUSIP 98420N105). La d茅claration indique une date d'茅v茅nement au 06/30/2025 et une signature dat茅e du 08/05/2025.
Holdings: La d茅tention b茅n茅ficiaire agr茅g茅e s'茅l猫ve 脿 8,824,363 actions, repr茅sentant 11.5% de la cat茅gorie. Sur la page de couverture, FMR LLC d茅clare un pouvoir de vote exclusif sur 8,824,348 actions, un pouvoir de disposition exclusif sur 8,824,363 actions, et aucun pouvoir de vote/disposition partag茅. Abigail P. Johnson est indiqu茅e avec un pouvoir de disposition exclusif sur 8,824,363 actions et aucun pouvoir de vote inscrit. Le d茅p么t pr茅cise que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur. L'Exhibit 99 et l'Exhibit 24 (procuration) sont mentionn茅s.
Filing: Schedule 13G/A eingereicht von FMR LLC und Abigail P. Johnson, die eine wirtschaftliche Beteiligung an XENON PHARMACEUTICALS INC (CUSIP 98420N105) melden. Die Erkl盲rung weist ein Ereignisdatum vom 06/30/2025 und ein Unterschriftsdatum vom 08/05/2025 aus.
Holdings: Die aggregierte wirtschaftliche Beteiligung betr盲gt 8,824,363 Aktien, was 11.5% der Klasse entspricht. Auf den Deckbl盲ttern meldet FMR LLC alleiniges Stimmrecht f眉r 8,824,348 Aktien, alleiniges Verf眉gungsrecht f眉r 8,824,363 Aktien und keine geteilten Stimm- oder Verf眉gungsrechte. Abigail P. Johnson wird mit alleinigem Verf眉gungsrecht 眉ber 8,824,363 Aktien und keinem Stimmrecht ausgewiesen. Die Einreichung gibt an, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten werden und nicht dazu dienen, die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen. Exhibit 99 und Exhibit 24 (Vollmacht) werden genannt.
FAQ
How many XENE shares does FMR LLC report beneficially owning?
What percentage of XENON PHARMACEUTICALS (XENE) does this represent?
What voting and dispositive powers are reported for FMR LLC and Abigail P. Johnson?
When is the event date and when was this Schedule 13G/A signed?
Does the filing claim the position is intended to influence control of XENE?
